Sign in
WithdrawnPhase 1/2

A Rollover Protocol of Elacestrant, in Combination With Onapristone, for Patients With ER+, PR+, HER2- Advanced or Metastatic Breast Cancer

Key facts

Who runs it
Context Therapeutics Inc.
Where
Nashville, United StatesSee the site
Trial code
Status
Withdrawn
Phase
Phase 1/2
Started
Jun 2023
Ended
Dec 2023
Type of study
Interventional
Treatments tested
  • Elacestrant
  • Onapristone
Record updated
22 April 2025
Why it stopped
Change in corporate strategy.

Who can take part

Age
18 years and older
Sex
Women only
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 5 criteriaShow less

Who can take part

  • Patient is currently enrolled in the ELONA clinical study (ONA-XR-103) and receiving onapristone or elacestrant, either alone or in combination
  • Patient is currently benefiting from the treatment in the ELONA clinical study, as determined by the investigator
  • Patient currently has no evidence of progressive disease, as determined by the investigator

Who cannot take part

  • Pregnant or nursing (lactating) women
  • Female patients of childbearing potential (e.g., are menstruating) who do not agree to abstinence or, if sexually active, do not agree to the use of highly effective contraception, throughout the study and for up to 30 days after stopping study treatment

Where in United States

  • Sarah Cannon Research InstituteNashville, United States

About the trial

What the trial wants to find out

This is a rollover study for patients enrolled in the discontinued ELONA clinical trial (ONA-XR-103) with the primary objective to characterize the safety of elacestrant in combination with onapristone either alone or in combination.

The group in the trial

  • Elacestrant / OnapristoneTreatment being tested

    Elacestrant and Onapristone combination

    Treatment: Elacestrant and Onapristone

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Rollover Protocol of Elacestrant, in Combination With Onapristone, for Patients With Estrogen Receptor-Positive, Progesterone Receptor-Positive, HER2-negative Advanced or Metastatic Breast Cancer
Record updated
22 April 2025